GPGeorge Panagis

George Panagis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


George Panagis has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Regulation of Brain Reward by the Endocannabinoid System: A Critical Review of Behavioral Studies in Animals

    by S. Vlachou, G. Panagis

    The endocannabinoid system has been implicated in the regulation of a variety of physiological processes, including a crucial involvement in brain reward systems and the regulation of motivational processes. Behavioral studies have shown that cannabinoid reward may involve the same brain circuits and similar brain mechanisms with other drugs of abuse, such as nicotine, cocaine, alcohol and heroin, as well as natural rewards, such as food, water and sucrose, although the conditions under which cannabinoids exert their rewarding effects may be more limited. The purpose of the present review is to briefly describe and evaluate the behavioral and pharmacological research concerning the major components of the endocannabinoid system and reward processes. Special emphasis is placed on data received from four procedures used to test the effects of the endocannabinoid system on brain reward in animals; namely, the intracranial self-stimulation paradigm, the self-administration procedure, the conditioned place preference procedure and the drug-discrimination procedure. The effects of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor agonists, antagonists and endocannabinoid modulators in these procedures are examined. Further, the involvement of CB1 and CB2 receptors, as well the fatty acid amid hydrolase (FAAH) enzyme in reward processes is investigated through presentation of respective genetic ablation studies in mice. We suggest that the endocannabinoid system plays a major role in modulating motivation and reward processes. Further research will provide us with a better understanding of these processes and, thus, could lead to the development of potential therapeutic compounds for the treatment of rewardrelated disorders.


  • Cannabidiol inhibits the reward‐facilitating effect of morphine: involvement of5‐HT1Areceptors in the dorsal raphe nucleus

    by Vicky Katsidoni, Ilektra Anagnostou, George Panagis

    Cannabidiol is a non‐psychotomimetic constituent ofCannabis sativa, which induces central effects in rodents. It has been shown that cannabidiol attenuates cue‐induced reinstatement of heroin seeking. However, to the best of our knowledge, its effects on brain stimulation reward and the reward‐facilitating effects of drugs of abuse have not yet been examined. Therefore, we investigated the effects of cannabidiol on brain reward function and on the reward‐facilitating effect of morphine and cocaine using the intracranial self‐stimulation (ICSS) paradigm. Rats were prepared with a stimulating electrode into the medial forebrain bundle (MFB), and a guide cannula into the dorsal raphe (microinjection experiments), and were trained to respond for electrical brain stimulation. A low dose of cannabidiol did not affect the reinforcing efficacy of brain stimulation, whereas higher doses significantly elevated the threshold frequency required forMFB ICSS. Both cocaine and morphine loweredICSSthresholds. Cannabidiol inhibited the reward‐facilitating effect of morphine, but not cocaine. This effect was reversed by pre‐treatment with an intra‐dorsal raphe injection of the selective5‐HT1Areceptor antagonistWAY‐100635. The present findings indicate that cannabidiol does not exhibit reinforcing properties in theICSSparadigm at any of the doses tested, while it decreases the reward‐facilitating effects of morphine. These effects were mediated by activation of5‐HT1Areceptors in the dorsal raphe. Our results suggest that cannabidiol interferes with brain reward mechanisms responsible for the expression of the acute reinforcing properties of opioids, thus indicating that cannabidiol may be clinically useful in attenuating the rewarding effects of opioids.


  • Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine

    by Vicky Katsidoni, Kalliopi Apazoglou, George Panagis

    Rationale The serotonin 5-HT2A and 5-HT2C receptors, which are found in abundance in the mesolimbocortical dopaminergic system, appear to modulate the behavioral effects of cocaine. Objectives The present series of studies set out to investigate the role of 5-HT2A and 5-HT2C receptors on brain reward and on the reward-facilitating effect of cocaine and localize the neural substrates within the mesolimbocortical dopaminergic system that are responsible for these effects. Methods Male Sprague-Dawley rats were implanted with stimulating electrodes and bilateral cannulae for the experiments involving microinjections and were trained to respond to electrical stimulation. In the first study, we examined the effects of systemic administration of selective 5-HT2A and 5-HT2C receptor agonists (TCB-2 and WAY-161503) and antagonists (R-96544 and SB-242084) on intracranial self-stimulation (ICSS). In the second study, we examined the effectiveness of TCB-2, WAY-161503, R-96544, and SB-242084 in blocking the reward-facilitating effect of cocaine. In the third study, we examined the effects of intra-medial prefrontal cortex (mPFC), intra-nucleus accumbens (NAC), and intra-ventral tegmental area (VTA) injection of WAY-161503 on the reward-facilitating effect of cocaine. Results Acute systemic administration of TCB-2 and WAY-161503 increased ICSS threshold. Systemic WAY-161503 attenuated the reward-facilitating effect of cocaine. This effect was reversed by pretreatment with SB-242084. Intracranial microinjections of WAY-161503 into the mPFC and the NAC shell/core, but not the VTA, attenuated the reward-facilitating effect of cocaine. Conclusion These data indicate that 5-HT2C receptors within the mPFC and the NAC modulate the reinforcing effects of cocaine and provide evidence that 5-HT2C receptor agonists could be a possible drug discovery target for the treatment of psychostimulant addiction.


  • Open Access

    Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania

    by Maria Mavrikaki, George G. Nomikos, George Panagis

    The atypical antipsychotic aripiprazole has been demonstrated to reduce symptoms of bipolar mania. To further profile the antimanic-like properties of


  • Behavioral Pharmacology of Cannabinoids with a Focus on Preclinical Models for Studying Reinforcing and Dependence-Producing Properties

    by George Panagis, Styliani Vlachou, George G. Nomikos

    Cannabis preparations as recreational drugs are the most widely used illicit drugs in the world. Although cannabis derivatives produce clear subjective motivational responses in humans leading to drug-seeking behavior and in a specific proportion in repeated drug use, the reinforcing/rewarding attributes of these subjective effects are difficult to define in experimental animals. This led to the notion of cannabinoids being considered as “atypical” or “anomalous” drugs of abuse. To this end, our knowledge and understanding of the way cannabis and its main psychoactive constituent, Δ9- tetrahydrocannabinol (Δ9-THC), act in the central nervous system to exert their reinforcing/rewarding effects is far from complete. The aim of the present article is to review from a preclinical perspective the current status of what is known about the behavioral pharmacology of cannabinoids including the recently identified cannabinoid neurotransmission modifiers with a particular emphasis on their motivational/reinforcing and dependence-producing properties. We conclude that cannabinoids exhibit reinforcing/rewarding properties in experimental animals mostly under particular experimental conditions, which is not the case for other drugs of abuse, such as opiates, psychostimulants, alcohol and nicotine. The paper will discuss these findings critically and also point to open questions that should be addressed in the future in order to improve our understanding of these specific actions of cannabinoids that will also impact drug discovery and development efforts of related compounds as therapeutics in the clinic.


  • Open Access

    Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine

    by Styliani Vlachou, Fygaleia Stamatopoulou, George G. Nomikos, George Panagis

    Cannabinoids, in contrast to typical drugs of abuse, have been shown to exert complex effects on behavioural reinforcement and psychomotor function. W


  • Effects of endocannabinoid neurotransmission modulators on brain stimulation reward

    by Styliani Vlachou, George G. Nomikos, George Panagis


  • CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat

    by Styliani Vlachou, George G. Nomikos, George Panagis

    Rationale Addictive drugs have a number of commonalities in animal behavioral models. They lower intracranial self-stimulation (ICSS) thresholds, support self-administration, and produce conditioned place preference (CPP). However, cannabinoids appear atypical as drugs of abuse, since there are controversial data in the literature concerning their reinforcing properties. Objectives The aim of the present study was to examine the effects of cannabinoids on brain reward using the rate–frequency curve shift paradigm of ICSS. Methods Male Sprague–Dawley rats were implanted with electrodes into the medial forebrain bundle (MFB). Rate–frequency functions were determined by logarithmically decreasing the number of cathodal pulses in a stimulation train from a value that sustained maximal responding to one that did not sustain responding. After brain stimulation reward thresholds stabilized rats received intraperitoneal (IP) injections of the potent CB1 receptor agonists WIN 55,212-2 (graded doses 0.1, 0.3, 1 and 3 mg/kg), CP 55,940 (graded doses 10, 30, 56 and 100 μg/kg), or HU-210 (graded doses 10, 30, 100 μg/kg). Results With the exception of the highest dose of all cannabinoid agonists tested, which significantly increased the threshold frequency required for MFB ICSS, all other doses of the tested drugs did not affect ICSS thresholds. The CB1 receptor antagonist SR141716A reversed the actions of WIN 55,212-2 and CP 55,940, but not HU-210. However, the selective CB1 cannabinoid receptor antagonist AM 251 counteracted the effect of HU-210. Both CB1 receptor antagonists, at the doses used in the present study, did not affect reward thresholds by themselves. Conclusions The present results indicate that cannabinoid agonists do not exhibit reinforcing properties in the ICSS paradigm, but rather have an inhibitory influence on reward mechanisms. The results suggest that the anhedonic effects of cannabinoids are probably mediated by cannabinoid CB1 receptors.